Inversago Pharma
in Peripheral CB1
Blockade
Full Potential of
Peripherally-acting
CB1 Inverse Agonists
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy.
The Peripheral CB1 Company
Targeting metabolic diseases in need of better adapted treatment options
Inversago has the know-how, technology and clinical expertise to develop safe and potent inverse agonists of peripheral CB1 receptors to address a broad range of medical indications (conditions related to obesity such as Prader-Willi syndrome (PWS), liver diseases (NASH) or diabetes (type 1 diabetes and diabetic nephropathy)).
INV-101, our lead program focusing on PWS and NASH, is a peripherally-acting CB1 inverse agonist in clinical development. Our other candidate molecules targeting the peripheral CB1 pathway have also shown activity in several preclinical models.
Our Approach
A safe and potent CB1 inhibitor would have the potential to block or reverse (inverse agonize) the biological processes induced by supraphysiological CB1 activation and provide a novel treatment to patients.